[go: up one dir, main page]

WO2012038832A3 - Génération de particules recombinantes chimères virus de la rougeole - rétrovirus - Google Patents

Génération de particules recombinantes chimères virus de la rougeole - rétrovirus Download PDF

Info

Publication number
WO2012038832A3
WO2012038832A3 PCT/IB2011/002586 IB2011002586W WO2012038832A3 WO 2012038832 A3 WO2012038832 A3 WO 2012038832A3 IB 2011002586 W IB2011002586 W IB 2011002586W WO 2012038832 A3 WO2012038832 A3 WO 2012038832A3
Authority
WO
WIPO (PCT)
Prior art keywords
measles virus
particles
retrovirus
generation
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2011/002586
Other languages
English (en)
Other versions
WO2012038832A2 (fr
Inventor
Thomas Jacques Gilles Mourez
Frédéric Tangy
Chantal Combredet
Valérie NAJBURG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Universite Paris Diderot Paris 7
Institut Pasteur
Original Assignee
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Universite Paris Diderot Paris 7
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Assistance Publique Hopitaux de Paris APHP, Universite Paris Diderot Paris 7, Institut Pasteur filed Critical Centre National de la Recherche Scientifique CNRS
Publication of WO2012038832A2 publication Critical patent/WO2012038832A2/fr
Publication of WO2012038832A3 publication Critical patent/WO2012038832A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des particules chimères virus de la rougeole - rétrovirus, en d'autres termes, des particules du virus de la rougeole (VR) exprimant les protéines d'enveloppe d'un rétrovirus, ou des régions immunogènes de celui-ci, sur sa surface. La présente invention fournit des moyens, en particulier des acides nucléiques, des vecteurs, des cellules et des systèmes de sauvetage pour cultiver ces particules chimères. L'invention concerne également l'utilisation de ces particules chimères, en particulier sous la forme d'une composition ou d'un vaccin, pour le traitement ou la prévention d'une infection par un rétrovirus, après l'induction d'une (de) réponse(s) immunitaire(s) cellulaire(s) et/ou humorale(s).
PCT/IB2011/002586 2010-09-24 2011-09-23 Génération de particules recombinantes chimères virus de la rougeole - rétrovirus Ceased WO2012038832A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38630410P 2010-09-24 2010-09-24
US61/386,304 2010-09-24

Publications (2)

Publication Number Publication Date
WO2012038832A2 WO2012038832A2 (fr) 2012-03-29
WO2012038832A3 true WO2012038832A3 (fr) 2012-05-24

Family

ID=45418711

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/002586 Ceased WO2012038832A2 (fr) 2010-09-24 2011-09-23 Génération de particules recombinantes chimères virus de la rougeole - rétrovirus

Country Status (1)

Country Link
WO (1) WO2012038832A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
EP2873728A1 (fr) * 2013-11-18 2015-05-20 Institut Pasteur Plateforme vaccinale de sous-unité à base de ribonucléoprotéines multimère comprenant des nucléoprotéines d'un virus ARN à brin négatif non segmenté en tant que supports de polypeptides hétérologues
EP3253874B1 (fr) * 2015-02-06 2022-03-23 Association Institut de Myologie Traitement de la dystrophie facioscapulohumérale
JP6616096B2 (ja) * 2015-04-27 2019-12-04 学校法人北里研究所 組換え麻疹ウイルス
JP2024502658A (ja) * 2021-01-13 2024-01-22 ヴィロキシ 麻疹－ｈｉｖ又は麻疹－ｈｔｌｖワクチン

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004001051A2 (fr) * 2002-06-20 2003-12-31 Institut Pasteur Virus de la rougeole recombines exprimant les epitopes d'antigenes d'arn virus, et utilisation dans la preparation de compositions vaccinales
EP1939214A1 (fr) * 2006-12-22 2008-07-02 Institut Pasteur Cellules et méthodes pour générer des virus à ARN, non-segmenté et de brin négatif

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004001051A2 (fr) * 2002-06-20 2003-12-31 Institut Pasteur Virus de la rougeole recombines exprimant les epitopes d'antigenes d'arn virus, et utilisation dans la preparation de compositions vaccinales
EP1939214A1 (fr) * 2006-12-22 2008-07-02 Institut Pasteur Cellules et méthodes pour générer des virus à ARN, non-segmenté et de brin négatif

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GUERBOIS M ET AL: "Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DELTAV1V2 is strongly immunogenic", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 388, no. 1, 25 May 2009 (2009-05-25), pages 191 - 203, XP026148640, ISSN: 0042-6822, [retrieved on 20090405], DOI: 10.1016/J.VIROL.2009.02.047 *
LORIN C ET AL: "A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type I clade B envelope glycoproteins induces neutralizing antibodies and cellular immune response to HIV", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 78, no. 1, 1 January 2004 (2004-01-01), pages 146 - 157, XP009080673, ISSN: 0022-538X, DOI: 10.1128/JVI.78.1.146-157.2004 *
MOUREZ T ET AL: "A chimeric measles virus with a lentiviral envelope replicates exclusively in CD4+/CCR5+ cells", VIROLOGY, vol. 419, no. 2, 3 September 2011 (2011-09-03), pages 117 - 125, XP055021380, ISSN: 0042-6822, DOI: 10.1016/j.virol.2011.08.007 *
MOUREZ T ET AL: "Generation of a new vaccine candidate based on a live measles/SIV chimera expressing gp160 on its surface", ABSTRACT # 364, POSTER SESSION G-106, 18TH CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI 2011), FEB 27-MAR 3 2011, BOSTON, 27 February 2011 (2011-02-27), XP055021385, Retrieved from the Internet <URL:http://www.retroconference.org/2011/PDFs/364.pdf> [retrieved on 20120308] *
TANGY F ET AL: "Replicating measles-SHIV vaccine induces preservation of central memmory CD4 in the gut of vaccinated macaques challenged with SHIV", 18 July 2010 (2010-07-18), XP002671209, Retrieved from the Internet <URL:http://pag.aids2010.org/Abstracts.aspx?SID=634&AID=13164> [retrieved on 20120308] *
TANGY F ET AL: "Replicating measles-SHIV vaccine induces preservation of central memmory CD4 in the gut of vaccinated macaques challenged with SHIV", 20 July 2010 (2010-07-20), XP002671208, Retrieved from the Internet <URL:http://pag.aids2010.org/flash/?pid=100438> [retrieved on 20120308] *

Also Published As

Publication number Publication date
WO2012038832A2 (fr) 2012-03-29

Similar Documents

Publication Publication Date Title
IN2015DN02546A (fr)
MX354750B (es) PARTÍCULAS PSEUDO-VIRALES (PPVs) QUE COMPRENDEN GLICOPROTEÍNAS DEL VIRUS DE LA RABIA.
GB2513768A (en) Complexes of cytomegalovirus proteins
AR080585A1 (es) Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias
DK2608806T3 (da) Epstein-barr-virusvaccine
MX387666B (es) Composiciones y su uso en el tratamiento de citomegalovirus
WO2010149752A3 (fr) Nouvelles compositions
PH12015500308B1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
IN2012DN03209A (fr)
MX2020000221A (es) Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas.
PH12016502554A1 (en) A dengue virus chimeric polyepitope composed of fragments of non structural proteins and its use in an immunogenic composition against dengue virus infection
WO2012047679A3 (fr) Produits de synthèse d&#39;antigène consensus et vaccins fabriqués à partir de ceux-ci, et procédés d&#39;utilisation de ceux-ci pour traiter le paludisme
UA110024C2 (uk) Вакцинний вектор і спосіб посилення імунної відповіді
WO2014004385A3 (fr) Vaccins anticancéreux
CA2863949A1 (fr) Antigenes largement reactifs optimises par ordinateur pour la grippe h5n1 humaine et aviaire
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
MX2019014674A (es) Virus recombinante de sarampion que expresa proteinas de virus zika y sus aplicaciones.
WO2012038832A3 (fr) Génération de particules recombinantes chimères virus de la rougeole - rétrovirus
MX350096B (es) Preservación asistida con vacío de productos biológicos, en particular de vacunas.
ZA202003070B (en) Lassa vaccine
EA200970731A1 (ru) Рекомбинантные антигены цитомегаловируса человека (hcmv)
HK1212708A1 (zh) H1n1流感的計算優化的寬反應性抗原
EA033242B1 (ru) Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением
WO2013173256A3 (fr) Versions nouvelles et améliorées de vaccins antigrippaux
WO2008027560A3 (fr) Vaccins et réactifs renforcés à la holine et procédés d&#39;utilisation correspondants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11802133

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11802133

Country of ref document: EP

Kind code of ref document: A2